F&G enters the stretch before its June 24 earnings call having delivered a remarkable 17% one-month rally — only to give back nearly 5% this week, leaving traders weighing whether the recent recovery is already spent or simply catching its breath.
The clearest standout on the stock right now is the CEO's behaviour in the lending pool. Short interest has climbed about 51% over the past month in raw share terms, jumping from roughly 1.6 million shares shorted in early April to just above 2.6 million. That takes SI to nearly 2% of the free float — still modest in absolute terms, but the pace of the build is notable. This week the trend reversed slightly, with SI trimming about 5% as the stock ticked back from recent highs. Borrow conditions offer little drama: cost to borrow is a near-frictionless 0.54%, and availability is deep — nothing in the lending data points to a crowded or constrained short. The ORTEX short score of 48.9 is squarely neutral, and the short score percentile rank of 14 confirms shorts are not the headline risk here.
Options positioning has tilted more defensive than usual. The put/call ratio reached 0.845 — about 1.4 standard deviations above its 20-day average of 0.77. That's a meaningful shift toward hedging over the past week or so, with the PCR drifting higher from readings comfortably below 0.72 in late April and early May. The move isn't extreme — the 52-week PCR range runs from 0.17 to 3.49 — but it corroborates the cautious tone suggested by the week's price action.
The analyst picture is thin but unambiguous on direction. Only two hold recommendations are on record. Barclays, the sole active coverage name, has spent over a year cutting its target: from $47 in early 2025 to $27 in April 2026, where the stock now actually trades. That April revision — maintaining Equal-Weight while dropping the target by $4 — puts the current consensus return potential at roughly -4%, meaning the Street's central case barely requires the stock to go anywhere from here. The P/E multiple of around 7x and a price-to-book just under 1x are undemanding, but the earnings-yield factor score of 95th percentile underlines that FG still looks cheap on earnings relative to the broader universe. The EPS surprise score at the 95th percentile is a genuine bright spot, signalling the company has been beating estimates consistently.
The insider register adds a layer of texture. CEO Christopher Blunt bought 10,000 shares in mid-March at roughly $21, shortly after the stock had sold off sharply. That purchase, at prices well below today's $28, reads as a vote of confidence after the weakness. The prior month, however, he sold over 20,800 shares at $22.65, as did the CFO and Executive Chairman — suggesting those February sales were more routine than directional. The net 90-day insider position is positive at roughly 68,000 shares, though the March buys were at much lower prices than where the stock trades today. On the institutional side, Fidelity National Financial holds a dominant 71% stake, limiting the freely traded float significantly, while BlackRock added a material 2.8 million shares in the most recent reporting period and Vanguard added nearly 1.8 million — two meaningful passive inflows that speak to index-related demand as FG's weight in relevant benchmarks adjusts.
The post-earnings history is brief but pointed. Following the May 7 Q1 results, the stock fell nearly 4% on the day. That follows a similarly negative reaction to prior prints, making the June 24 Q2 event one where the price reaction — rather than the beat/miss itself — is what the options market now appears to be positioning around. The RSI-14 of 54.8 puts the stock in neutral technical territory after the month's bounce, neither overbought nor building momentum. Close peers LNC and FNF both fell harder this week — down 6.5% and 7.0% respectively — while PRU and CNO held up far better, each ending the week in positive territory. That divergence within the insurance group makes the next few weeks a useful test of whether FG's recent recovery was idiosyncratic or simply riding a sector tide that has now turned.
What to watch next: whether the PCR drift toward defensiveness deepens or reverses ahead of June 24, and whether the short interest build that accelerated through April and May resumes after this week's modest unwind.
See the live data behind this article on ORTEX.
Open FG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
